{"DataElement":{"publicId":"3049856","version":"1","preferredName":"Mitotic Index Nuclear Antigen Tumor Present Text","preferredDefinition":"Text description of the mitotic index, the ratio between the number of cells in mitosis and the total number of cells, using against the nuclear antigen Ki-67 or MIB.","longName":"MITIND_NUC_ANT_TXT","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"3049852","version":"1","preferredName":"Mitotic Index Nuclear Antigen Present","preferredDefinition":"Pertaining to mitosis._Index; a numerical scale used to compare variables with one another or with some reference number._Pertaining to the nucleus._Any substance that appears foreign or potentially adverse to the body and elicits immune response._Being or existing in a specified place or at the specified time","longName":"MITIND_NUC_ANT_PRES","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"3049850","version":"1","preferredName":"Mitotic Index Nuclear Antigen","preferredDefinition":"Pertaining to mitosis.:Index; a numerical scale used to compare variables with one another or with some reference number.:Pertaining to the nucleus.:Any substance that appears foreign or potentially adverse to the body and elicits immune response.","longName":"C37993:C25390:C13361:C268","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mitotic","conceptCode":"C37993","definition":"Pertaining to mitosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Index","conceptCode":"C25390","definition":"A numerical scale used to compare variables with one another or with some reference number; a number used to select an element of a list, vector, array or other sequence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Nuclear","conceptCode":"C13361","definition":"Pertaining to the nucleus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Antigen","conceptCode":"C268","definition":"Any substance, generally a protein, that stimulates the immune system and elicits an immune response.  Recognition by the immune system elicits either a T-lymphocyte response, recognizing processed antigens, or a B-lymphocyte response, producing antibodies that bind to unprocessed antigens.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"838D91A3-8D64-848A-E040-BB89AD433CBD","latestVersionIndicator":"Yes","beginDate":"2010-04-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-06","modifiedBy":"ONEDATA","dateModified":"2010-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233878","version":"1","preferredName":"Present","preferredDefinition":"Being or existing in a specified place or at the specified time.","longName":"C25626","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Present","conceptCode":"C25626","definition":"Being or existing in a specified place or at the specified time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F970CDF6-F829-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"ONEDATA","dateModified":"2005-06-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435012","version":"1","preferredName":"Biochemical Pathway","preferredDefinition":"An elaboration of the sequence of chemical reactions leading from one compound to another taking place in living tissue.","longName":"C20633","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D7-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"838D91A3-8D72-848A-E040-BB89AD433CBD","latestVersionIndicator":"Yes","beginDate":"2010-04-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-06","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3049854","version":"1","preferredName":"Neoplasm Mitotic Index Text","preferredDefinition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation.  Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia.  Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._The percentage of cells in a sample currently undergoing mitosis._Text; the words of something written.","longName":"TUM_MITIND_TXT","context":"CCR","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"30","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2435012","version":"1","preferredName":"Biochemical Pathway","preferredDefinition":"An elaboration of the sequence of chemical reactions leading from one compound to another taking place in living tissue.","longName":"C20633","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D7-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3049853","version":"1","preferredName":"Neoplasm S-Phase Fraction Text","preferredDefinition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.:The percentage of cells in a sample currently undergoing mitosis.:Text; the words of something written.","longName":"C3262:C18456:C25704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"S-Phase Fraction","conceptCode":"C18456","definition":"The percentage of cells in a sample currently undergoing mitosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"838D91A3-8D87-848A-E040-BB89AD433CBD","latestVersionIndicator":"Yes","beginDate":"2010-04-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-06","modifiedBy":"ONEDATA","dateModified":"2010-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"838D91A3-8D98-848A-E040-BB89AD433CBD","latestVersionIndicator":"Yes","beginDate":"2010-04-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-06","modifiedBy":"ONEDATA","dateModified":"2010-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Mitotic Index","type":"Preferred Question Text","description":"Mitotic Index","url":null,"context":"CCR"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"838D91A3-8DAB-848A-E040-BB89AD433CBD","latestVersionIndicator":"Yes","beginDate":"2010-04-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-06","modifiedBy":"REEVESD","dateModified":"2014-05-21","changeDescription":"Curated for CCR Brain tumor trial","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}